Cowen & Co. Maintains a Hold Rating on Radius Health (RDUS)

Cowen & Co. analyst Chris Shibutani maintained a Hold rating on Radius Health (RDUS) today. The company’s shares closed yesterday at $22.51.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 7.6% and a 44.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Radius Health with a $29.67 average price target.

See today’s analyst top recommended stocks >>

Based on Radius Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $42.76 million. In comparison, last year the company had a GAAP net loss of $68.88 million.

Based on the recent corporate insider activity of 35 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RDUS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis.